HC Wainwright reissued their buy rating on shares of BioAtla ( NASDAQ:BCAB – Free Report ) in a research note published on Wednesday morning, Benzinga reports. The firm currently has a $17.00 target price on the stock. HC Wainwright also issued estimates for BioAtla's Q3 2023 earnings at ($0.71) EPS, Q4 2023 earnings at ($0.72) EPS, Q1 2024 earnings at ($0.62) EPS, Q2 2024 earnings at ($0.60) EPS, Q3 2024 earnings at ($0.58) EPS, Q4 2024 earnings at ($0.53) EPS, FY2024 earnings at ($2.33) EPS, FY2025 earnings at ($1.

https://www.dailypolitical.com/2023/08/06/bioatla-nasdaqbcab-given-buy-rating-at-hc-wainwright.html

#dailypolitical